Lion Corporation (LIOPY) Fair Value & Analysis
Consumer Defensive · US · Market cap $2.3B
Analysis
Lion Corporation (LIOPY) currently trades at $16.40, while our model-based Fair Value estimate is $23.26 — implying the stock looks roughly 41.8% undervalued today. We read business quality at 88/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Lion Corporation manufactures and sells consumer and industrial products in Japan and internationally. It operates through Consumer Goods, Industrial Products, and Overseas segments. The company provides oral healthcare products, including toothpastes, toothbrushes and cleaning tools, dental rinses and mouthwashes, periodontitis ointments, and denture products; beauty care products, such as shampoos and conditioners, hand soaps, sanitizers, wet wipes, hygiene care, body washes, acne care, antiperspirants and deodorants, men's care, and foot and heel care products, as well as oral health habit support program. It offers antipyretic analgesics, eye drops and eye care products, cold medicines, gargles, cold relief products, antidiarrheal, gastrointestinal, acne, and anti-drowsiness medicines, and dermatologic agents. In addition, the company offers fabric care and detergents products; household cleaners; and kitchen cleanup products. Further, it also provides pet healthcare and living …
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.